Adamis Pharmaceuticals has recalled Symjepi® (epinephrine) injection 0.15mg (0.15mg/ 0.3mL) and 0.3mg (0.3mg/0.3mL) pre-filled single-dose syringes. The syringe needles of the affected lots may become clogged, which can prevent the proper dispensing of epinephrine.

• There is no impact to members through Benecard Central
• Symjepi is indicated for emergency treatment of allergic reactions including anaphylaxis, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis.
• If a syringe malfunctions, patients may not receive the correct dose of medication, putting them at risk of life-threatening consequences. Adamis has received two customer complaints about difficulty dispensing medication from three syringes. However, the company states these complaints have not been confirmed as being related to the recall. Adamis had received no reports of adverse events connected to the recall as of March 22, 2022.
• According to Adamis, consumers and institutions that have Symjepi subject to the recall should stop using it immediately and either return or discard Questions regarding the recall should be directed to US WorldMeds at 1-888-900-8796 or medinfo@usworldmeds.com.
• A full copy of the recall notice, including affected lot numbers, is available on the FDA website.